Article
Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
PloS one - 1 Jan 2015
Bessette Darrell C, Tilch Erik, Seidens Tatjana, Quinn Michael C J, Wiegmans Adrian P, Shi Wei, Cocciardi Sibylle, McCart-Reed Amy, Saunus Jodi M, Simpson Peter T, Grimmond Sean M, Lakhani Sunil R, Khanna Kum Kum, Waddell Nic, Al-Ejeh Fares, Chenevix-Trench Georgia
Abstract excerpt
BACKGROUND: Basal-like and triple negative breast cancer (TNBC) share common molecular features, poor prognosis and a propensity for metastasis to the brain. Amplification of epidermal growth factor receptor (EGFR) occurs in ~50% of basal-like breast cancer, and mutations in the epidermal growth factor receptor (EGFR) have been reported in up to ~ 10% of Asian TNBC patients. In non-small cell lung cancer several...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.